SpringerLink
Log in

Clinical Evaluation and Management of Chronic Lymphocytic Leukemia

  • Chapter
  • First Online:
Concise Guide to Hematology

  • 2815 Accesses

Abstract

Chronic lymphocytic leukemia (CLL) is the most leukemia in the United States and is characterized by clonal expansion of CD5-positive B cells. The diagnosis of CLL requires the presence of greater than or equal to 5 × 109/L clonal B-lymphocytes in the peripheral blood. Most patients with CLL do not need treatment at the time of diagnosis. Common indications for treatment include worsening lymphadenopathy, organomegaly, or development of cytopenias. Chemoimmunotherapy has been the standard treatment for patients with CLL. In the last few years, several novel targeted therapy agents have been developed targeting CLL cells. With the introduction of these agents such as ibrutinib, idelalisib, and venetoclax, the role of chemotherapy for patients with CLL has declined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126:463–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. SEER Database. https://seer.cancer.gov/statfacts/html/clyl.html.

  3. Yang SM, Li JY, Gale RP, Huang XJ. The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? Blood Rev. 2015;29:205–13.

    PubMed  Google Scholar 

  4. Mak V, Ip D, Mang O, Dalal C, Huang S, et al. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leuk Lymphoma. 2014;55:824–7.

    PubMed  Google Scholar 

  5. Slager SL, Benavente Y, Blair A, Vermeulen R, Cerhan JR, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:41–51.

    PubMed  PubMed Central  Google Scholar 

  6. Radivoyevitch T, Sachs RK, Gale RP, Smith MR, Hill BT. Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. Leuk Res. 2016;43:9–12.

    CAS  PubMed  Google Scholar 

  7. Brown JR. Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. Ther Adv Hematol. 2013;4:298–308.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.

    CAS  Google Scholar 

  9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.

    CAS  PubMed  Google Scholar 

  10. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.

    CAS  PubMed  Google Scholar 

  11. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–75.

    CAS  PubMed  Google Scholar 

  13. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893–901.

    CAS  PubMed  Google Scholar 

  14. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    CAS  PubMed  Google Scholar 

  16. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365:2497–506.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126:454–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–90.

    Google Scholar 

  21. Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016;128:2093–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016;91:1090–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30:457–9.

    CAS  PubMed  Google Scholar 

  24. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19–25.

    CAS  PubMed  Google Scholar 

  25. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–91.

    CAS  PubMed  Google Scholar 

  26. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:793–8.

    CAS  Google Scholar 

  27. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370:230–9.

    CAS  PubMed  Google Scholar 

  28. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27:4378–84.

    CAS  Google Scholar 

  29. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183:749–58.

    CAS  PubMed  Google Scholar 

  30. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28:1749–55.

    CAS  Google Scholar 

  31. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23:4079–88.

    CAS  Google Scholar 

  32. Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30:3209–16.

    CAS  Google Scholar 

  33. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.

    CAS  PubMed  Google Scholar 

  34. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–10.

    CAS  PubMed  Google Scholar 

  35. Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–4.

    CAS  PubMed  Google Scholar 

  36. Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–83.

    CAS  PubMed  Google Scholar 

  37. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.

    CAS  PubMed  Google Scholar 

  38. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30:980–8.

    Google Scholar 

  40. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2016;34:3758–65.

    CAS  Google Scholar 

  42. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. O'Brien S, Furman RR, Coutre SE, Flinn IW, Burger J, et al. Five-year experience with single-agent Ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128:233.

    Google Scholar 

  45. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–805.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    PubMed  PubMed Central  Google Scholar 

  47. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.

    PubMed  PubMed Central  Google Scholar 

  49. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

    CAS  PubMed  Google Scholar 

  50. Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148–67.

    CAS  PubMed  Google Scholar 

  51. Lampson BL, Brown JR. PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017;26:1267–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–94.

    PubMed  PubMed Central  Google Scholar 

  55. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.

    CAS  Google Scholar 

  57. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22.

    CAS  PubMed  Google Scholar 

  58. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Seymour JF, Kipps TJ, Eichhorst BF, Hillmen P, D’Rozario JM, et al. Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia – results from pre-planned interim analysis of the randomized phase 3 Murano Study. Blood. 2017;130:LBA-2-LBA.

    Google Scholar 

  60. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol : Off J Am Soc Clin Oncol. 2006;24:5343–9.

    CAS  Google Scholar 

  62. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118:3489–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122:734–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib. J Clin Oncol : Off J Am Soc Clin Oncol. 2017;35:3010–20.

    CAS  Google Scholar 

  68. Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124:3841–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2008;450:6.

    Google Scholar 

  70. Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev. 2018;32:106–15.

    CAS  PubMed  Google Scholar 

  71. Cortes J, O’Brien S, Loscertales J, Kantarjian H, Giles F, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001;92:2016–22.

    CAS  PubMed  Google Scholar 

  72. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81:121–6.

    CAS  PubMed  Google Scholar 

  73. Rossi D, Gaidano G. Richter syndrome. Adv Exp Med Biol. 2013;792:173–91.

    CAS  PubMed  Google Scholar 

  74. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123:2783–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391–401.

    CAS  PubMed  Google Scholar 

  76. Jain N, Keating MJ. Richter transformation of CLL. Expert Rev Hematol. 2016;9:793–801.

    CAS  PubMed  Google Scholar 

  77. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142:202–15.

    CAS  PubMed  Google Scholar 

  78. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122:2673–82.

    CAS  PubMed  Google Scholar 

  79. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210:2273–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013;13:568–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, et al. Nivolumab combined with Ibrutinib for CLL and Richter transformation: a phase II trial. Blood. 2016;128:59.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nitin Jain

  2. Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA

    Susan O’Brien

Authors
  1. Nitin Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan O’Brien .

Editor information

Editors and Affiliations

  1. Department of Medicine, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Department of Medicine, University Hospital Cleveland Medical Center, Cleveland, OH, USA

    Alvin H. Schmaier

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jain, N., O’Brien, S. (2019). Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. In: Lazarus, H., Schmaier, A. (eds) Concise Guide to Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-97873-4_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97873-4_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97872-7

  • Online ISBN: 978-3-319-97873-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation